<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.111057</article-id><article-id pub-id-type="publisher-id">ACM-40156</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210100000_57190510.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  NLR与慢性阻塞性肺疾病并肺癌一线化疗疗效的关系
  Relationship between NLR and Efficacy of First-Line Chemotherapy for Chronic Obstructive Pulmonary Disease with Lung Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>杰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>叶</surname><given-names>兴</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>段</surname><given-names>传洲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青岛市市立医院，山东 青岛</addr-line></aff><aff id="aff2"><addr-line>潍坊医学院临床医学院，山东 潍坊</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>01</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>403</fpage><lpage>409</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：本研究旨在探讨化疗开始前外周血中性粒细胞/淋巴细胞比值(neutrophil-to-lymphocyte ratio, NLR)对慢性阻塞性肺疾病(chronic obstructive pulmonary disease，简称：慢阻肺)并肺癌患者一线化疗疗效的预测作用。方法：回顾性分析2014年01月~2020年01月于青岛市市立医院呼吸与危重症医学科住院治疗的66例慢性阻塞性肺疾病并肺癌患者，并以NLR的中位数3.95为依据，划为低NLR组和高NLR组，分析入组患者的病历资料和一线化疗疗效。结果：低NLR组和高NLR组患者在年龄、性别、吸烟史、TNM分期、组织病理类型和一线化疗方案上，差异无统计学意义(P &gt; 0.05)。低NLR组近期化疗疗效明显优于高NLR组，差异有统计学意义(P &lt; 0.05)。结论：化疗开始前外周血NLR与进行一线化疗方案治疗的慢性阻塞性肺疾病并肺癌患者的近期化疗疗效密切相关，外周血NLR有可能成为预测慢性阻塞性肺疾病并肺癌一线化疗效果的理想指标。
    Object: The purpose of this study was to investigate the predictive value of neutrophil to lymphocyte ratio (NLR) in patients with chronic obstructive pulmonary disease (COPD) and lung cancer before chemotherapy. Methods: From January 2014 to January 2020, 66 patients with chronic obstructive pulmonary disease and lung cancer in the Department of Respiratory and Critical Care Medicine of Qingdao Municipal Hospital were retrospectively analyzed. According to the median NLR of 3.95, they were divided into the high NLR group and the low NLR group. Results: There was no significant difference in age, gender, smoking history, TNM stage, histopathological type and first-line chemotherapy between the high NLR group and the low NLR group (P &gt; 0.05). The short-term chemotherapy effect of the low NLR group was significantly better than that of the high NLR group (P &lt; 0.05). Conclusion peripheral blood NLR before chemotherapy is closely related to the short-term chemotherapy efficacy of patients with COPD and lung cancer treated with first-line chemotherapy. Peripheral blood NLR may be an ideal index to predict the effect of first-line chemotherapy for COPD and lung cancer. 
  
 
</p></abstract><kwd-group><kwd>慢性阻塞性肺疾病，肺癌，中性粒细胞/淋巴细胞比值，化疗疗效, Chronic Obstructive Pulmonary Disease</kwd><kwd> Lung Cancer</kwd><kwd> Neutrophile Granulocyte</kwd><kwd> Lymphocyte Ratio</kwd><kwd> Chemotherapeutic Efficacy</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：本研究旨在探讨化疗开始前外周血中性粒细胞/淋巴细胞比值(neutrophil-to-lymphocyte ratio, NLR)对慢性阻塞性肺疾病(chronic obstructive pulmonary disease，简称：慢阻肺)并肺癌患者一线化疗疗效的预测作用。方法：回顾性分析2014年01月~2020年01月于青岛市市立医院呼吸与危重症医学科住院治疗的66例慢性阻塞性肺疾病并肺癌患者，并以NLR的中位数3.95为依据，划为低NLR组和高NLR组，分析入组患者的病历资料和一线化疗疗效。结果：低NLR组和高NLR组患者在年龄、性别、吸烟史、TNM分期、组织病理类型和一线化疗方案上，差异无统计学意义(P &gt; 0.05)。低NLR组近期化疗疗效明显优于高NLR组，差异有统计学意义(P &lt; 0.05)。结论：化疗开始前外周血NLR与进行一线化疗方案治疗的慢性阻塞性肺疾病并肺癌患者的近期化疗疗效密切相关，外周血NLR有可能成为预测慢性阻塞性肺疾病并肺癌一线化疗效果的理想指标。</p></sec><sec id="s2"><title>关键词</title><p>慢性阻塞性肺疾病，肺癌，中性粒细胞/淋巴细胞比值，化疗疗效</p></sec><sec id="s3"><title>Relationship between NLR and Efficacy of First-Line Chemotherapy for Chronic Obstructive Pulmonary Disease with Lung Cancer<sup> </sup></title><p>Jie Zhang<sup>1</sup>, Xing Ye<sup>2</sup>, Chuanzhou Duan<sup>1*</sup></p><p><sup>1</sup>Clinical Medicine College, Weifang Medical University, Weifang Shandong</p><p><sup>2</sup>Qingdao Municipal Hospital, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/57-1571891x5_hanspub.png" /></p><p>Received: Dec. 28<sup>th</sup>, 2020; accepted: Jan. 21<sup>st</sup>, 2021; published: Jan. 29<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/57-1571891x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Object: The purpose of this study was to investigate the predictive value of neutrophil to lymphocyte ratio (NLR) in patients with chronic obstructive pulmonary disease (COPD) and lung cancer before chemotherapy. Methods: From January 2014 to January 2020, 66 patients with chronic obstructive pulmonary disease and lung cancer in the Department of Respiratory and Critical Care Medicine of Qingdao Municipal Hospital were retrospectively analyzed. According to the median NLR of 3.95, they were divided into the high NLR group and the low NLR group. Results: There was no significant difference in age, gender, smoking history, TNM stage, histopathological type and first-line chemotherapy between the high NLR group and the low NLR group (P &gt; 0.05). The short-term chemotherapy effect of the low NLR group was significantly better than that of the high NLR group (P &lt; 0.05). Conclusion peripheral blood NLR before chemotherapy is closely related to the short-term chemotherapy efficacy of patients with COPD and lung cancer treated with first-line chemotherapy. Peripheral blood NLR may be an ideal index to predict the effect of first-line chemotherapy for COPD and lung cancer.</p><p>Keywords:Chronic Obstructive Pulmonary Disease, Lung Cancer, Neutrophile Granulocyte, Lymphocyte Ratio, Chemotherapeutic Efficacy</p><disp-formula id="hanspub.40156-formula42"><graphic xlink:href="//html.hanspub.org/file/57-1571891x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/57-1571891x8_hanspub.png" /> <img src="//html.hanspub.org/file/57-1571891x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>2018年我国肺健康研究(CPH)结果显示慢阻肺患者人数已接近1亿，40岁以上人口占14% [<xref ref-type="bibr" rid="hanspub.40156-ref1">1</xref>]，在全球影响将近2亿人，预计到2030年将成为全球第三大死亡原因 [<xref ref-type="bibr" rid="hanspub.40156-ref2">2</xref>]。肺癌是发病率和死亡率居高不下的恶性肿瘤 [<xref ref-type="bibr" rid="hanspub.40156-ref3">3</xref>]，也是全球死亡率最高的恶性肿瘤之一 [<xref ref-type="bibr" rid="hanspub.40156-ref4">4</xref>]。越来越多的证据表明慢性炎症、氧化应激等在促进慢阻肺转化为肺癌过程中发挥着至关重要的作用 [<xref ref-type="bibr" rid="hanspub.40156-ref5">5</xref>]，慢性阻塞性肺疾病患者中肺癌的发病率较正常人群肺癌发病率高，相比较单纯的肺癌患者来说，慢阻肺并肺癌患者肺功能、生活质量及预后差 [<xref ref-type="bibr" rid="hanspub.40156-ref6">6</xref>]，然而，由于慢性阻塞性肺疾病临床症状的影响，让合并肺癌患者不易被诊断，甚至出现误诊，大部分患者明确诊断时已是肺癌晚期，对于其中一部分患者来说以铂类为基础一线化疗方案仍然是治疗的主要措施，但是患者异质性较大，对化疗治疗有不同的疗效反应，迫切寻找一种可以预测疗效的指标及改善预后的干预措施。目前很多研究发现外周血NLR可预测某些实体瘤的化疗疗效和预后，使其成为预测某些肿瘤一线化疗效果的理想指标 [<xref ref-type="bibr" rid="hanspub.40156-ref7">7</xref>]。但NLR对慢性阻塞性肺疾病并肺癌一线化疗的预测作用研究甚少。现就化疗前NLR对慢性阻塞性肺疾病并肺癌患者一线化疗疗效的预测作用作一探究。</p></sec><sec id="s6"><title>2. 临床资料与研究方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>随机收集2014年1月~2020年1月于青岛市市立医院呼吸与危重症医学科住院治疗的符合入组标准的66例慢性阻塞性肺疾病并肺癌患者(男50例，女16例)，中位年龄63岁(年龄范围在39~85岁之间)，其中鳞癌有37例、腺癌有23例、其他有6例，有吸烟史48例，TNM分期：III期35例、IV期31例，化疗方案：GP方案37例、DP方案6例、PC方案23例。本研究经过医院伦理委员会批准，所有患者均签署知情同意书。</p></sec><sec id="s6_2"><title>2.2. 研究对象</title><p>纳入标准：组织学病理诊断为非小细胞肺癌，有完善的影像学资料[胸腹部计算机断层扫描(computed tomography, CT)、头颅磁共振成像(magnetic resonance imaging, MRI)]可供肿瘤分期评价；肿瘤分期包括不可手术切除的III期和IV期患者，一线化疗期间每2周期完善胸腹部增强CT和头颅MRI检查；未接受过任何抗肿瘤治疗(包括放射治疗、化学治疗、生物治疗、免疫治疗、靶向治疗及中药治疗)；ECOG评分 ≤ 2分，血常规正常，耐受以铂类为基础的两药联合一线化疗的初治患者。</p><p>排除标准：组织学病理为小细胞肺癌；合并两种或两种以上肿瘤；合并血液系统疾病；合并免疫系统疾病；治疗前分期评价不足；治疗期间未进行影像学采集可供疗效评价；在一线化疗期间出现不可逆重度骨髓抑制；一线化疗间隔推迟2个月以上；肝功肾功受损；重症感染伴有发热。</p></sec><sec id="s6_3"><title>2.3. 检测方法</title><p>所有符合纳入标准的慢性阻塞性肺疾病并肺癌患者于化疗开始前3天采集空腹血常规。送入青岛市市立医院检验科行血常规检测，NLR是以血常规中中性粒细胞计数与淋巴细胞计数的比值计算。并以中位数3.95为依据划为低NLR组和高NLR组 [<xref ref-type="bibr" rid="hanspub.40156-ref8">8</xref>]。</p></sec><sec id="s6_4"><title>2.4. 治疗方法</title><p>所有入组患者根据美国国家综合癌症网络指南治疗：该研究中，在低NLR组中进行GP (Gemcitabine Cisplatin 吉西他滨 顺铂)方案化疗治疗有16例，DP (Docetaxel Cisplatin 多西他赛 顺铂)方案有5例，PC (Pemetrexed Cisplatin 培美曲塞 顺铂)方案有12例，在高NLR组中进行GP方案化疗治疗有21例，DP方案有1例，PC方案有11例。</p></sec><sec id="s6_5"><title>2.5. 疗效评价</title><p>临床分期根据国际肺癌研究协会颁布的第7版分期标准进行评估 [<xref ref-type="bibr" rid="hanspub.40156-ref9">9</xref>]。近期疗效评价标准根据实体瘤RECIST 1.1疗效评价，将疗效分为：完全缓解CR (complete remission)，部分缓解PR (partial remission)，疾病稳定SD (stable disease)，疾病进展PD (progressive disease) [<xref ref-type="bibr" rid="hanspub.40156-ref10">10</xref>]。</p></sec><sec id="s6_6"><title>2.6. 统计学分析</title><p>应用SPSS 23.0统计学软件进行分析。采用中位数表示计量资料，采用例数或百分数表示分类资料，采用χ2检验和Fisher确切概率法进行组间比较，采用两独立样本的秩和检验进行组间比较。以P &lt; 0.05表示差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 化疗前NLR与病历资料的关系</title><p>33例低NLR和33例高NLR的慢性阻塞性肺疾病并肺癌患者在年龄、性别、吸烟史、分期、组织病理类型和一线化疗方案上，差异无统计学意义(P &gt; 0.05) (见表1)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> 66 cases of chronic obstructive pulmonary disease with lung cance</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >病历资料</th><th align="center" valign="middle" >低NLR</th><th align="center" valign="middle" >高NLR</th><th align="center" valign="middle"  rowspan="2"  >χ<sup>2</sup></th><th align="center" valign="middle"  rowspan="2"  >P</th></tr></thead><tr><td align="center" valign="middle" >(n = 33)</td><td align="center" valign="middle" >(n = 33)</td></tr><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >1.000</td></tr><tr><td align="center" valign="middle" >&lt;65</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥65</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.320</td><td align="center" valign="middle" >0.251</td></tr><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >27</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >吸烟史</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.222</td><td align="center" valign="middle" >0.269</td></tr><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >无</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >TNM分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.547</td><td align="center" valign="middle" >0.459</td></tr><tr><td align="center" valign="middle" >III期</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >IV期</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >组织病理类型</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.767<sup>*</sup></td></tr><tr><td align="center" valign="middle" >鳞癌</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >腺癌</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >其他</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >一线化疗方案</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.219<sup>*</sup></td></tr><tr><td align="center" valign="middle" >GP</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >DP</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >PC</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表1. 66例慢性阻塞性肺疾病并肺癌患者的病历资料</p><p>注：<sup>*</sup>Fisher确切概率法。</p></sec><sec id="s7_2"><title>3.2. 化疗疗效及NLR的预测作用</title><p>在完成两周期化疗后，由青岛市市立医院呼吸与危重症医学科三位主任医师进行化疗疗效综合评估。结果示：33例低NLR组中CR有0例、PR有12例、SD有16例、PD有5例，高NLR组中CR有0例、PR有6例、SD有12例、PD有15例，低NLR组一线化疗疗效显著优于高NLR组，差异具有统计学意义(P &lt; 0.05) (见表2)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of curative effect between the two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分组</th><th align="center" valign="middle" >CR</th><th align="center" valign="middle" >PR</th><th align="center" valign="middle" >SD</th><th align="center" valign="middle" >PD</th><th align="center" valign="middle" >Z</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >低NLR (n = 33)</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >2.590</td><td align="center" valign="middle" >0.010</td></tr><tr><td align="center" valign="middle" >高NLR (n = 33)</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表2. 两组患者的疗效比较</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>最近多项流行病学研究表示，COPD与肺癌之间存在密切联系 [<xref ref-type="bibr" rid="hanspub.40156-ref11">11</xref>]，肺癌在慢阻肺人群中明显升高，40%~70%肺癌患者合并慢阻肺，发现慢阻肺是肺癌的独立危险因素 [<xref ref-type="bibr" rid="hanspub.40156-ref12">12</xref>]，可能与其有共同的发病因素有关。慢性阻塞性肺疾病并肺癌患者临床症状严重、肺功能差、预后差，给患者及国家医疗资源带来沉重负担 [<xref ref-type="bibr" rid="hanspub.40156-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.40156-ref14">14</xref>]。随着医学的发展可给患者提供精准的个体化治疗，其靶向、免疫等治疗已取得较好的疗效，但是仍有一部分不幸患者无基因治疗的靶点，以铂类为基础的两药联合化疗方案可以使晚期肺癌的死亡率降低27%，延长肺癌患者的中位期和总生存期，因此，以铂类为基础的化疗方案仍处于重要地位 [<xref ref-type="bibr" rid="hanspub.40156-ref15">15</xref>]。但是由于异质性的原因，即使进行同一种化疗治疗方案，不同患者的疗效也存在很大差别，我们渴望发现一种可以预测疗效的安全方便的理想指标，并拟通过积极干预获得更好的治疗效果。</p><p>慢性炎症是COPD和肺癌的常见发病原因，持续存在的慢性炎症会导致肺泡干细胞增殖，提高上皮细胞对致癌物的敏感性，诱导上皮细胞转换为肺癌细胞，同时，肺癌细胞又可分泌中性粒细胞中的蛋白质促进炎症反应 [<xref ref-type="bibr" rid="hanspub.40156-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.40156-ref17">17</xref>]。在其他炎症与癌症中也有类似的发现，比如肝炎与肝癌、胃炎与胃癌、结肠炎与结肠癌，慢性炎症与癌症之间有一种相互促进的关系。NLR机体系统性炎症和免疫失衡的指标，当NLR值升高时，中性粒细胞计数相对增多，淋巴细胞计数相对减少，使得平衡状态被打破，炎性反应向着促肿瘤方向发展 [<xref ref-type="bibr" rid="hanspub.40156-ref18">18</xref>]。并在胃癌、结直肠癌、乳腺癌等多种肿瘤中证实与疗效及预后显著相关 [<xref ref-type="bibr" rid="hanspub.40156-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.40156-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.40156-ref21">21</xref>]。Yao等在182例肺癌患者中发现高NLR组铂类药物一线化疗疗效差 [<xref ref-type="bibr" rid="hanspub.40156-ref22">22</xref>]。Peng等荟萃分析表明高NLR与疗效呈反比 [<xref ref-type="bibr" rid="hanspub.40156-ref23">23</xref>]。Botta等报道在肺癌的治疗中高NLR组贝伐单抗疗效更差 [<xref ref-type="bibr" rid="hanspub.40156-ref24">24</xref>]。李曦颖通过193例肺腺癌发现NLR水平在化疗前及第2、4周期化疗后疾病PD组均高于CR组 + PR组 + SD组(P &lt; 0.01)，化疗前NLR是生存期的独立危险因素，差异有统计学意义，反应出高NLR水平影响了患者的化疗效果 [<xref ref-type="bibr" rid="hanspub.40156-ref25">25</xref>]。类似的研究发现NLR是无敏感突变的非鳞状非小细胞肺癌患者长期化疗获益的独立预测因素，NLR较低的患者是铂类药物化疗的最佳人选 [<xref ref-type="bibr" rid="hanspub.40156-ref26">26</xref>]。Neringa Vaguliene发现在慢性阻塞性肺疾病并肺癌患者中NLR水平较慢性阻塞性肺疾病升高 [<xref ref-type="bibr" rid="hanspub.40156-ref27">27</xref>]。这些证据似乎表明NLR在慢性阻塞性肺疾病并肺癌患者中起到一定的作用，可能预测慢性阻塞性肺疾病并肺癌患者的铂类一线化疗疗效。在我们的研究中，通过分析33例低NLR和33例高NLR的慢性阻塞性肺疾病并肺癌患者一线化疗效果的差异情况，结果发现低NLR组一线化疗疗效显著优于高NLR组，我们本次的研究结果与既往在晚期肺癌中的研究结果相似。我国学者易福梅发现2周期化疗后患者的NLR水平与一线化疗2周期和4周期的疗效密切相关(P &lt; 0.05)，疾病进展患者中高NLR的比例为100.0%，显著高于部分缓解和疾病稳定的患者 [<xref ref-type="bibr" rid="hanspub.40156-ref28">28</xref>]。本研究的局限性在于样本量偏小，存在选择性偏倚可能，而且没有动态观察化疗过程中NLR水平的变化，需要进一步大样本量的前瞻性临床研究进行验证。</p></sec><sec id="s9"><title>5. 结论</title><p>综上可见，对进行以铂类为基础的两药联合一线化疗方案治疗的慢性阻塞性肺疾病并肺癌患者，化疗前外周血NLR与近期化疗治疗效果密切相关，很可能是预测一线化疗疗效的理想指标，也可能是慢性阻塞性肺疾病并肺癌患者治疗的潜在干预靶点，对于高水平的NLR患者，为提高铂类化疗药物疗效，改善患者预后，应早期进行干预。</p></sec><sec id="s10"><title>文章引用</title><p>张 杰,叶 兴,段传洲. NLR与慢性阻塞性肺疾病并肺癌一线化疗疗效的关系Relationship between NLR and Efficacy of First-Line Chemotherapy for Chronic Obstructive Pulmonary Disease with Lung Cancer[J]. 临床医学进展, 2021, 11(01): 403-409. https://doi.org/10.12677/ACM.2021.111057</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40156-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Wang, C., Xu, J., Yang, L., et al. (2018) Prevalence and Risk Factors of Chronic Obstructive Pulmonary Disease in China (the China Pulmonary Health [CPH] Study): A National Cross-Sectional Study. The Lancet, 391, 1706-1717.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(18)30841-9</mixed-citation></ref><ref id="hanspub.40156-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">McGregor, H.C., Short, M.A., McWilliams, A., et al. (2017) Real-Time Endoscopic Raman Spectroscopy for in Vivo Early Lung Cancer Detection. Journal of Biophotonics, 10, 98-110. &lt;br&gt;https://doi.org/10.1002/jbio.201500204</mixed-citation></ref><ref id="hanspub.40156-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">中国肿瘤临床与康复编辑部. 2017年中国最新癌症数据[J]. 中国肿瘤临床与康复, 2017, 24(6): 760.</mixed-citation></ref><ref id="hanspub.40156-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会, 中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2018版) [J]. 中华肿瘤杂志, 2018, 40(12): 935-964.</mixed-citation></ref><ref id="hanspub.40156-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Zeneyedpour, L., Dekker, L.J.M., van Sten-van, T., Hoff, J.J.M., et al. (2019) Neoantigens in Chronic Obstructive Pulmonary Disease and Lung Cancer: A Point of View. Proteomics Clinical Applications, 13, e1800093.  
&lt;br&gt;https://doi.org/10.1002/prca.201800093</mixed-citation></ref><ref id="hanspub.40156-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">徐汉章. 慢性阻塞性肺疾病合并肺癌患者肺功能、免疫功能及营养状态研究[J]. 中国现代药物应用, 2020, 14(6): 46-47.</mixed-citation></ref><ref id="hanspub.40156-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Templeton, A.J., McNamara, M.G., Seruga, B., et al. (2014) Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 106, dju124.  
&lt;br&gt;https://doi.org/10.1093/jnci/dju124</mixed-citation></ref><ref id="hanspub.40156-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Diem, S., Schmid, S., Krapf, M., et al. (2017) Neutrophil-to-Lymphocyteratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as Prognostic Markers in Patients with Nonsmall Cell Lung Cancer (NSCLC) Treated with Nivolumab. Lung Cancer, 111, 176-181. &lt;br&gt;https://doi.org/10.1016/j.lungcan.2017.07.024</mixed-citation></ref><ref id="hanspub.40156-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Detterbeck, F.C., Boffa, D.J. and Tanoue, L.T. (2009) The New Lung Cancer Staging System. Chest, 136, 260-271.  
&lt;br&gt;https://doi.org/10.1378/chest.08-0978</mixed-citation></ref><ref id="hanspub.40156-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Nishino, M., Jackman, D.M., Hatabu, H., et al. (2010) New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Nonsmall Cell Lung Cancer: Comparison with Original RECIST and Impact on Assessment of Tumor Response to Targeted Therapy. AJR American Journal of Roentgenology, 195, W221-W228.  
&lt;br&gt;https://doi.org/10.2214/AJR.09.3928</mixed-citation></ref><ref id="hanspub.40156-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Sears, C.R. (2019) DNA Repair as an Emerging Target for COPD-Lung Cancer Overlap. Respiratory Investigation, 57, 111-121. &lt;br&gt;https://doi.org/10.1016/j.resinv.2018.11.005</mixed-citation></ref><ref id="hanspub.40156-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Koshiol, J., Rotunno, M., Consonni, D., et al. (2009) Chronic Obstructive Pulmonary Disease and Altered Risk of Lung Cancer in a Population-Based Case-Control Study. PLoS ONE, 4, e7380.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0007380</mixed-citation></ref><ref id="hanspub.40156-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">王学林. 慢性阻塞性肺疾病合并肺癌的临床特点分析[J]. 临床医学, 2019, 39(2): 27-28.</mixed-citation></ref><ref id="hanspub.40156-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">王丹, 庞敏. 慢性阻塞性肺疾病合并肺癌的临床特征分析[J]. 临床肺科杂志, 2019, 24(6): 1082-1085.</mixed-citation></ref><ref id="hanspub.40156-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">胡洁, 白春学. 肺癌的规范化治疗[J]. 内科急危重症杂志, 2014, 20(5): 294-298.</mixed-citation></ref><ref id="hanspub.40156-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Sekine, Y., Katsura, H., Koh, E., et al. (2012) Early Detection of COPD Is Important for Lung Cancer Surveillance. European Respiratory Journal, 39, 1230. &lt;br&gt;https://doi.org/10.1183/09031936.00126011</mixed-citation></ref><ref id="hanspub.40156-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Durham, A.L. and Adcock, I.M. (2015) The Relationship between COPD and Lung Cancer. Lung Cancer, 90, 121-127.  
&lt;br&gt;https://doi.org/10.1016/j.lungcan.2015.08.017</mixed-citation></ref><ref id="hanspub.40156-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Chen, L., Kong, X., Yan, C., et al. (2020) The Research Progress on the Prognostic Value of the Common Hematological Parameters in Peripheral Venous Blood in Breast Cancer. OncoTargets and Therapy, 13, 1397-1412.  
&lt;br&gt;https://doi.org/10.2147/OTT.S227171</mixed-citation></ref><ref id="hanspub.40156-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Miyamoto, R., Inagawa, S., Sano, N., et al. (2018) The Neutrophil-to-Lymphocyte Ratio (NLR) Predicts Short-Term and Long-Term Outcomes in Gastric Cancer Patients. European Journal of Surgical Oncology, 44, 607-612.  
&lt;br&gt;https://doi.org/10.1016/j.ejso.2018.02.003</mixed-citation></ref><ref id="hanspub.40156-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, J., Zhang, H.Y., Li, J., et al. (2017) The Elevated NLR, PLR and PLT May Predict the Prognosis of Patients with Colorectal Cancer: A Systematic Review and Meta-Analysis. Oncotarget, 8, 68837-68846.  
&lt;br&gt;https://doi.org/10.18632/oncotarget.18575</mixed-citation></ref><ref id="hanspub.40156-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Iimori, N., Kashiwagi, S., Asano, Y., et al. (2018) Clinical Significance of the Neutrophil-to-Lymphocyte Ratio in Endocrine Therapy for Stage IV Breast Cancer. In Vivo, 32, 669-675. &lt;br&gt;https://doi.org/10.21873/invivo.11292</mixed-citation></ref><ref id="hanspub.40156-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Yao, Y., Yuan, D., Liu, H., et al. (2013) Pretreatment Neutrophil to Lymphocyte Ratio Is Associated with Response to Therapy and Prognosis of Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy. Cancer Immunology, Immunotherapy, 62, 471-479. &lt;br&gt;https://doi.org/10.1007/s00262-012-1347-9</mixed-citation></ref><ref id="hanspub.40156-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Peng, B., Wang, Y.H., Liu, Y.M., et al. (2015) Prognostic Significance of the Neutrophil to Lymphocyte Ratio in Patients with Non-Small Cell Lung Cancer: A Systemic Review and Meta-Analysis. International Journal of Clinical and Experimental Medicine, 8, 3098-3106.</mixed-citation></ref><ref id="hanspub.40156-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Botta, C., Barbieri, V., Ciliberto, D., et al. (2013) Systemic Inflammatory Status at Baseline Predicts Bevacizumab Benefit in Advanced Non-Small Cell Lung Cancer Patients. Cancer Biology &amp; Therapy, 14, 469-475.  
&lt;br&gt;https://doi.org/10.4161/cbt.24425</mixed-citation></ref><ref id="hanspub.40156-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">李曦颖, 黄礼年. 动态监测NLR、PLR变化与晚期肺腺癌一线化疗疗效及预后关系[J]. 蚌埠医学院学报, 2020, 45(11): 1486-1490.</mixed-citation></ref><ref id="hanspub.40156-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Li, X., Zeng, W.H., Zhou, Y.Q., et al. (2019) Neutrophil-to-Lymphocyte Ratio Predicted Long-Term Chemotherapy Benefits in Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer Patients without Sensitive Mutations. OncoTargets and Therapy, 12, 8779-8787. &lt;br&gt;https://doi.org/10.2147/OTT.S225544</mixed-citation></ref><ref id="hanspub.40156-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Vaguliene, N., Zemaitis, M., Lavinskiene, S., et al. (2013) Local and Systemic Neutrophilic Inflammation in Patients with Lung Cancer and Chronic Obstructive Pulmonary Disease. BMC Immunology, 14, 36.  
&lt;br&gt;https://doi.org/10.1186/1471-2172-14-36</mixed-citation></ref><ref id="hanspub.40156-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">易福梅, 顾阳春, 陈森, 刘燕娥, 尹文琤, 张煜, 曹宝山. 治疗前后NLR和PLR对进展期非小细胞肺癌一线化疗疗效及预后的预测价值[J]. 中国肺癌杂志, 2018, 21(6): 481-492.</mixed-citation></ref></ref-list></back></article>